Israel Englander’s Cellectis CLLS Stock Holding History

Israel Englander’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,000	Closed	-$460K	–	5983
2020 Q4	$460K	Buy	+17,000	New	+$381K	﹤0.01%	4254

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Israel Englander's CLLS Position: Q4 2025 in Review

Israel Englander sold out of Cellectis (CLLS) in Q4 2025, closing a stake of 57,740 shares — an estimated $165K sold.

Israel Englander first reported a position in CLLS in Q1 2015 and held it in 38 quarters. The position peaked at $5.82M in Q4 2015. 34 funds tracked by Wall St. Rank hold CLLS as of Q4 2025.

Israel Englander reported no remaining Cellectis position as of Q4 2025 after selling out during the quarter.
Israel Englander sold 57,740 Cellectis shares in Q4 2025, an estimated $165K.
Israel Englander first reported a position in Cellectis in Q1 2015 and held it in 38 quarters.
Israel Englander's Cellectis position peaked at $5.82M in Q4 2015.
34 funds tracked by Wall St. Rank held Cellectis as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.